Her2 positive breast cancer
Conditions
Interventions
Case series: Pyrotinib combined therapy
Sponsors
The First Affiliated Hospital of Guangxi Medical Universtiy
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed positive expression of HER2 in patients with recurrent/metastatic breast cancer; 2. Patients who agree and are able to pass the ICH test for hormone receptor status; 3. Patients who volunteer to participate in this study, sign informed consent, have good compliance and are willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Inability to swallow, chronic diarrhea, and intestinal obstruction can affect medication use and absorption; 2. Pregnant and lactating female patients; 3. According to the researcher's judgement,there are serious risks to patient safety or concomitant diseases that affect the completion of the study(Including but not limited to severe hypertension beyond the control of drugs, severe diabetes, active infection, severe heart failure, etc.); 4. The researchers consider the patients are unfit to participate in this study with any other conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| ECOG score;vital signs;physical examination;Laboratory inspection index;ECG;ultrasonic cardiogram;Quality of Life;adverse event;National Cancer Institute-Common Toxicity Critera Adverse Event 4.0; | — |
Countries
China
Contacts
Public ContactZeng Jian
The First Affiliated Hospital of Guangxi Medical Universtiy
Outcome results
None listed